Official SEC submissions
AstraZeneca SEC Filings
Direct answer
AstraZeneca's latest SEC filing is 6-K.
Get free AstraZeneca email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Recent SEC filings
6-K
Current report
Filed:
Report date:
ADMISSION OF FURTHER SECURITIES TO TRADING
6-K
Current report
Filed:
Report date:
ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING
6-K
Current report
Filed:
Report date:
ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC
6-K
Current report
Filed:
Report date:
ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY
6-K
Current report
Filed:
Report date:
TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG
6-K
Current report
Filed:
Report date:
TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS
6-K
Current report
Filed:
Report date:
ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING
6-K
Current report
Filed:
Report date:
ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
6-K
Current report
Filed:
Report date:
UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL
6-K
Current report
Filed:
Report date:
TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
6-K
Current report
Filed:
Report date:
ADMISSION OF FURTHER SECURITIES TO TRADING
6-K
Current report
Filed:
Report date:
DATROWAY APPROVED IN EU FOR TNBC
6-K
Current report
Filed:
Report date:
UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA
6-K
Current report
Filed:
Report date:
SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS
6-K
Current report
Filed:
Report date:
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER
6-K
Current report
Filed:
Report date:
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR
6-K
Current report
Filed:
Report date:
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
6-K
Current report
Filed:
Report date:
ADMISSION OF FURTHER SECURITIES TO TRADING
6-K
Current report
Filed:
Report date:
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS
6-K
Current report
Filed:
Report date:
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC
6-K
Current report
Filed:
Report date:
TRUQAP APPROVED IN US FOR PROSTATE CANCER
6-K
Current report
Filed:
Report date:
ADMISSION OF FURTHER SECURITIES TO TRADING
6-K
Current report
Filed:
Report date:
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
6-K
Current report
Filed:
Report date:
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
6-K
Current report
Filed:
Report date:
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
6-K
Current report
Filed:
Report date:
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
6-K
Current report
Filed:
Report date:
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
6-K
Current report
Filed:
Report date:
BAXFENDY APPROVED IN THE US FOR HYPERTENSION
Verified data
- Recent filing categories
- 2
- Recent filings
- 40
- SEC CIK
- 0000901832
- Latest filing date
- September 1, 2026